Previous 10 | Next 10 |
2023-03-22 18:43:05 ET Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Conference Call March 22, 2023, 04:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group LLC Talat Imran - CEO Svai Sanford - CFO Mir Hashim - Chief Sc...
2023-03-22 16:23:37 ET Rani Therapeutics press release ( NASDAQ: RANI ): Q4 GAAP EPS of -$0.35 in-line. Net loss for the three and twelve months ended December 31, 2022 was $17.3 million and $63.3 million, respectively, compared to $13.3 million and $53.1 million for the s...
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway fo...
SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release ...
SAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with...
- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis - SAN JOSE, Calif., Jan. 05, 2023 (GLOBE NEWSW...
- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavail...
Rani Therapeutics press release ( NASDAQ: RANI ): Q3 GAAP EPS of -$0.33. Cash, cash equivalents, restricted cash equivalents and marketable securities as of September 30, 2022 totaled $98.7 million, compared to cash and cash equivalents of $117.5 million for the year ended...
- RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis ...
SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company wil...
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
Rani Therapeutics Holdings Inc. Website:
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and Pr...
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will parti...